Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nipocalimab by Johnson & Johnson for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)....
Nipocalimab by Johnson & Johnson for Primary Sjogren's Syndrome: Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase II for Primary Sjogren's Syndrome. According to...
Nipocalimab by Johnson & Johnson for Myasthenia Gravis: Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase III for Myasthenia Gravis. According to GlobalData,...
Nipocalimab by Johnson & Johnson for Rheumatoid Arthritis: Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase II for Rheumatoid Arthritis. According to GlobalData,...
Nipocalimab by Johnson & Johnson for Erythroblastosis Fetalis (Hemolytic Disease In Newborns): Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase III for Erythroblastosis Fetalis (Hemolytic Disease In...
Risk adjusted net present value: What is the current valuation of Johnson & Johnson's Nipocalimab?
Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic...